Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Impax I

Impax Small Cap Fund Investor Class (PXSCX)

Ticker PXSCX · · Holdings as of Jun 30, 2026

Expense ratio
1.16%$116/yr per $10k
5-yr return
+7.8%annualized
1-yr return
+11.5%as of Dec 2025
Net assets
$949.2Mall share classes
Holdings
62

Bottom line

Is PXSCX a good fund? The bottom line

PXSCX is the Investor Class share class of Impax Small Cap Fund, a managed small-cap mutual fund from Impax I.

It charges 1.16% — about $116 a year on every $10,000 invested, more expensive than 66% of small-cap funds we track.

It returned +11.5% over one year, +7.8% a year over five years, +8.0% a year over ten (as of Dec 31, 2025, per its prospectus).

With $949 million in net assets and 62 holdings, its largest position is Ligand Pharmaceuticals, Inc. (5.1%) and the top 10 make up 30.7% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What PXSCX invests in

The Small Cap Funds investment objective is to seek long-term growth of capital.

The Small Cap Fund follows a sustainable investing approach, investing in companies that the Adviser believes are well positioned to benefit from the transition to a more sustainable global economy, integrating a proprietary corporate resilience (Corporate Resilience) (formerly known as ESG) analysis that considers governance structures, the management of material environmental and social risks, climate risks (physical and transition), human capital management, and controversies (such analysis, Corporate Resilience Analysis) into portfolio construction and managing the portfolio within certain risk parameters (e.g., sector and regional exposure) relative to the Funds benchmark universe of Russell 2000 Index companies. The Fund utilizes the Impax Sustainability Lens, a proprietary tool designed to facilitate a systematic review of the economic opportunities and risks associated with the…

From the fund's prospectus (filed Apr 24, 2026).

PXSCX performance

Fund calendar-year total returns, 2016–2025 2016: +17.9%; 2017: +8.8%; 2018: −15.8%; 2019: +23.3%; 2020: +11.8%; 2021: +30.2%; 2022: −23.0%; 2023: +13.5%; 2024: +14.5%; 2025: +11.5% +18% 2016 +9% 2017 −16% 2018 +23% 2019 +12% 2020 +30% 2021 −23% 2022 +14% 2023 +15% 2024 +11% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PXSCX+11.5%+7.8%+8.0%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full PXSCX performance history →

What PXSCX costs

On a $10,000 investment, PXSCX's 1.16% expense ratio costs about $116 a year. The prospectus estimates $1,409 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full PXSCX fee table →

PXSCX top 10 holdings

#Holding% of fund
1Ligand Pharmaceuticals, Inc.5.08%
2Victory Capital Holdings, Inc.4.65%
3Eastern Bankshares, Inc.2.99%
4Mitek Systems, Inc.2.88%
5Neurocrine Biosciences, Inc.2.84%
6Acadian Asset Management, Inc.2.64%
7Teradata Corp.2.50%
8SI-BONE, Inc.2.45%
9Onto Innovation, Inc.2.35%
10Pinnacle Financial Partners, Inc.2.29%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to PXSCX

More funds like PXSCX →

PXSCX FAQ

What is the expense ratio of PXSCX?
PXSCX's expense ratio is 1.16%, which works out to about $116 a year for every $10,000 invested. The prospectus estimates total costs of $1,409 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PXSCX a good investment?
It depends on your goals, but the data points to: no front-end sales load; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does PXSCX hold?
PXSCX's largest holdings are Ligand Pharmaceuticals, Inc. (5.1%), Victory Capital Holdings, Inc. (4.6%), Eastern Bankshares, Inc. (3.0%), Mitek Systems, Inc. (2.9%), Neurocrine Biosciences, Inc. (2.8%). It holds 62 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is PXSCX's 5-year return?
PXSCX returned +7.8% a year over the five years ending Dec 31, 2025, and +8.0% a year over ten years. Past performance does not guarantee future results.
Does PXSCX have a sales load?
No. PXSCX has no front-end sales charge.
Who manages PXSCX?
PXSCX is offered by Impax I through Impax Funds Series Trust I.